logo
Sign In
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research PanelFor OfficesFor Institutions
Prescribing toolsPrescribing InfoCoverageSavingsA-Z IndicationsCompare Drugs
CompanyAboutCareersContact UsSecurity
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Samples
    3. Inluriyo (imlunestrant)
    Inluriyo (imlunestrant) sample image
    Eli Lilly and Co.Inluriyo (imlunestrant)Inluriyo (imlunestrant) tablets
    Indications and Usage

    INDICATIONS AND USAGE

    INLURIYO is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 ( ESR1 )-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.

    FAQsAll you need to know to order samples
    Due to manufacturer restrictions, there are some limitations on the quantities of samples that can be included in each order. We're working on new functionality to let your practice place larger, batch orders.
    At this time, PrescriberPoint is only available in the U.S, but we hope to expand our reach in the future! Follow us or sign up for our newsletter to stay up to date on all things PrescriberPoint, including new market launches.
    After Manufacturer approval, orders typically ship in 1-2 business days and take 2-4 days to arrive via USPS.

    Your privacy is important to us. Please read our Terms & Conditions and Privacy Policy. If you have questions or comments, please contact us at support@prescriberpoint.com